Document:

Exhibit
10.2

 

June
15, 2017

 

Dear
Wes,

 

As
an executive employee of TearLab Research, Inc., (the “Company”), you are aware of the potential for a future sale
of the Company. For the benefit of employees and Company shareholders, it may be helpful in securing favorable sales terms to
reduce the severance obligations of the Company under certain existing executive contracts, including your contract dated May
15, 2015. Accordingly, the Company is offering you the voluntary choice to enter into an amendment to your employment contract
dated June 15, 2017

 

Should
you choose to agree to the amendment, the Exhibit B (ORIGINAL) to your employment contract will be replaced with the attached
Exhibit B AMENDED. Please carefully read Exhibit B AMENDED in its entirety. Should you agree to the amendment, the terms and obligations
of your employment set forth in your original employment contract that were not contained in Exhibit B are not changed by the
amendment. You should be aware that your employment with the Company will remain at-will. As a result, you are free to resign
at any time, for any reason or for no reason. Similarly, the Company is free to conclude its employment relationship with you
at any time, with or without cause, and with or without notice. We request that, in the event of resignation, you give the Company
at least 30 days’ notice. Notwithstanding the foregoing, you may be entitled to certain severance benefits upon a qualifying
termination of your employment, as provided in Exhibit B AMENDED.

 

Should
you agree to the amendment, this letter and the corresponding Exhibit B AMENDED, along with the provisions of your original employment
contract that are not impacted by the amendment, shall constitute your entire employment contract with the Company. The provisions
of your employment contract, including, but not limited to, its at-will employment provisions, may not be modified or amended
except by a written agreement signed by the Chief Executive Officer of the Company and you.

 

	 	Sincerely,
	 	
	 	Seph
    Jensen
	 	Chief
    Executive Officer

 

I
FURTHER ACKNOWLEDGE THAT I HAVE ENTERED INTO THIS AGREEMENT VOLUNTARILY AND HAVE NOT BEEN FORCED OR COERCED INTO DOING SO.

 

Agreed
to and accepted:

 

	Signature:	/s/
    Wes Brazell	 
	Printed
    Name:	Wes
    Brazell	 
	Date:	June
    15, 2017	 

 

    	 	 	 

     

    

 

Exhibit
B AMENDED

 

Termination
by Executive

 

You
may terminate your employment with the Company at any time by providing the Company with at least thirty (30) days of notice in
writing. During the resignation notice period, you will be required to perform the duties set forth in this letter. Notwithstanding,
upon receipt of your resignation (other than with respect to a resignation within twelve (12) months of the occurrence of a Change
in Control as defined below), the Company may, in its sole and absolute discretion, terminate your employment before the date
the resignation was to be effective, and the Company will, in full satisfaction of its obligations to you: (a) continue to pay
your base salary in accordance with the Company’s payroll practices until the date the resignation was to be effective up
to a maximum of three (3) months, subject to the terms and conditions of Exhibit A of your employment contract; (b) reimburse
the outstanding expenses properly incurred by you until the date your employment ceases; and (c) pay you a pro-rated bonus in
a lump sum calculated as at the date your employment ceases as soon as administratively practicable after the termination by the
Company, but in no event will any such pro-rated bonus be paid after the later of: (i) the fifteenth (15th) day of the third (3rd)
month after the end of the Company’s fiscal year in which such bonus is earned, or (ii) March 15 following the calendar
year in which such bonus is earned.

 

Termination
by Company for Cause, Death or Disability

 

The
Company may terminate your employment at any time with Cause and without prior notice or any further obligations by the Company.
On the termination of your employment for cause or on your death or disability, the Company will, in full satisfaction of its
obligations to you: (a) pay your base salary and vacation pay accrued until the date your employment ceases; and (b) reimburse
the outstanding expenses properly incurred by you until the date your employment ceases. You will not be entitled to any other
payments (including severance or bonus) should you be terminated for Cause.

 

For
the purposes of this Exhibit, a termination for “Cause” occurs in the event you are terminated because:

 

	 	(1)	You
    breach your employment contract;
	 	 	 
	 	(2)	You
    commit an act of dishonesty, fraud, or misrepresentation, or other acts of moral turpitude, including acts that jeopardize
    the Company’s reputation or relationship with its employees, shareholders, clients, vendors or affiliates;
	 	 	 
	 	(3)	You
    violate your duty of loyalty to the Company;
	 	 	 
	 	(4)	You
    misappropriate or fail to protect the Company’s proprietary and or confidential information, or that of the Company’s
    clients, partners, or affiliates;
	 	 	 
	 	(5)	You
    are convicted of a felony;
	 	 	 
	 	(6)	You
    die or become disabled in a manner that prevents you from being able to perform the essential functions of your job with reasonable
    accommodation.

 

If
your termination occurs due to your death or disability, you will be entitled to a pro-rated bonus calculated as at the date your
employment ceases, which shall be paid in a lump sum as soon as administratively practicable after your death or disability, but
in no event will any such pro-rated bonus be paid after the later of: (i) the fifteenth (15th) day of the third (3rd) month after
the end of the Company’s fiscal year in which such bonus is earned, or (ii) March 15 following the calendar year in which
such bonus is earned.

 

    	 	 	 

     

    

 

Termination
by Company without Cause or Resignation on Change of Control

 

The
Company may terminate your employment at any time without cause on providing written notice, and if it does terminate you without
cause the Company will pay you the severance benefits outlined in subdivision (a) and (b) below. Also, you may resign due to a
Material Adverse Change in your terms and conditions of employment within twelve (12) months following the occurrence of a Change
in Control as defined below, on providing written notice within thirty (30) days of the events constituting a Material Adverse
Change and a cure period of not less than thirty (30) days for the Company to cure any such Material Adverse Change; provided,
however, that such resignation must occur within thirty (30) days following the end of such cure period. If the Company terminates
your employment without cause or if you resign within twelve (12) months of a Change in Control due to a Material Adverse Change
and after providing the required notice and cure period, then subject to the terms and conditions of Exhibit C, the Company
will, in full satisfaction of its obligations to you:

 

(a)
Pay a lump sum amount equal to: (i) one (1) times your annual base salary in effect at the time of the termination; plus (ii)
one (1) times the average of the bonus paid to you in the two (2) years preceding the year of termination; and

 

(b)
Reimburse you for the cost of group health benefit plan premiums for up to twelve 12) months from the date your employment ceases.
Such reimbursements shall be made concurrent with any obligation owed to you by the Company under the U.S. federal COBRA law to
the extent applicable. Notwithstanding the foregoing, if the Company determines in its sole discretion that it cannot provide
the foregoing COBRA premium reimbursements without potentially violating, or being subject to an excise tax under, applicable
law (including, without limitation, Section 2716 of the Public Health Service Act), the Company will in lieu thereof provide to
you a taxable monthly payment, payable on the last day of a given month (except as provided by the following sentence), in an
amount equal to the monthly COBRA premium that you would be required to pay to continue the group health coverage for you and/or
your eligible dependents in effect on the termination of employment date (which amount will be based on the premium for the first
month of COBRA coverage), which payments will be made regardless of whether you and/or your eligible dependents elect COBRA continuation
coverage and will commence on the month following your termination of employment and will end on the earlier of (x) the date upon
which you obtain other employment or (y) the date the Company has paid an amount equal to twelve (12) payments. Any such taxable
monthly payments that otherwise would have been paid to you within the sixty (60) days following your termination date instead
will be paid on the sixty-first (61st) day following your termination of employment, with any remaining payments paid as provided
in the prior sentence (subject to any delay as may be required by Appendix C). For the avoidance of doubt, the taxable payments
in lieu of COBRA reimbursements may be used for any purpose, including, but not limited to continuation coverage under COBRA,
and will be subject to all applicable tax withholdings.

 

As
set forth in Exhibit C to your employment contract, your receipt of any severance benefits under this Agreement or otherwise is
expressly conditioned upon your execution of a complete and general release of all claims that may be released as a mater of law.

 

    	 	 	 

     

    

 

Change
of Control and “Material Adverse Change”

 

“Change
of Control” means:

 

(a)
any transaction or series of transactions, whether by way of consolidation, amalgamation or merger of the Company, with or into
any other person, other than an affiliate of the Company as defined in the Ontario Business Corporations Act as amended (an “Affiliate”);

 

(b)
any transfer, conveyance, sale, lease, exchange or otherwise of all or substantially all of the assets of the Company, to any
other person, other than an Affiliate;

 

(c)
more than fifty percent (50%) of the directors of the Company in office (i) were not directors of the Company on the same day
in the immediately preceding calendar year and (ii) were not proposed by the directors of the Company existing prior to their
appointment or election;

 

(d)
the lawful acquisition, directly or indirectly and by any means whatsoever, by any person, or by a group of persons acting jointly
or in concert, of that number of voting shares of the Company, which is forty percent (40%) or more of the total voting shares
issued and outstanding immediately after such acquisition, unless another person or group of persons has previously lawfully acquired
and continues to hold a number of voting units which represents a greater percentage than the first-mentioned person or group
of persons; or

 

(e)
the directors of the Company by resolution deem that a Change in Control has occurred or is about to occur.

 

Consequences
of Termination

 

Upon
termination of your employment for any reason, the Company will pay your base salary and vacation pay accrued until the date your
employment ceases and reimburse your expenses properly incurred until the date your employment ceases. The termination of your
employment terminates any officer positions you may hold pursuant to this letter, and you agree to sign any documentation necessary
to give effect to this Exhibit B, or to give effect to any pro forma resolutions of the Company in respect of the period
prior to termination of your employment.

 

Bonus
Upon Change of Control of the Company

 

If
you are employed on the day a Change of Control of the Company occurs, then the Company shall pay you a bonus of Twenty Thousand
Dollars ($20,000.00) subject to customary payroll taxes and deductions, within 30 days of the finalization of the Change of Control
of the Company.

 

    	 	 	 

     

    

 

Exhibit
C

 

To
the extent any severance benefits will be made under this letter, they will be delayed as necessary pursuant to (A) the Release
requirement described below and (B) the provisions of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the
“Code”), and the final regulations and any guidance promulgated thereunder and any applicable state law equivalents
(“Section 409A”), each as outlined below.

 

Release
Requirement 

 

The
receipt of any severance pay and benefits under this letter is subject to you signing and not revoking a standard release of claims
with the Company (the “Release”) and provided that the Release becomes effective and irrevocable within sixty (60)
days following your termination of employment (such deadline, the “Release Deadline”). If the Release does not become
effective and irrevocable by the Release Deadline, you will forfeit any rights to severance benefits under this letter.

 

Severance
pay and benefits under this letter will commence or be paid, as applicable, on the sixtieth (60th) day following the date of your
termination of employment, or, if later, such time as required by the paragraphs below. Except as required by the paragraphs below,
any lump sum or installment payments that would have been made to you during the sixty (60) day period immediately following your
termination of employment but for the preceding sentence will be paid on the first payroll period following the sixtieth (60th)
day following your termination of employment and the remaining payments will be made as provided in this letter.

 

Section
409A

 

Notwithstanding
anything to the contrary in this letter, no severance benefits to be paid or provided to you, if any, pursuant to this letter
or otherwise that, when considered together with any other severance payments or separation benefits, are considered deferred
compensation under Section 409A (together, the “Deferred Payments”) will be paid or otherwise provided until you have
a “separation from service” within the meaning of Section 409A. Similarly, no severance payable to you, if any, pursuant
to this letter that otherwise would be exempt from Section 409A pursuant to U.S. Treasury Regulation Section 1.409A-1(b)(9) will
be payable until you have a “separation from service” within the meaning of Section 409A.

 

Notwithstanding
anything to the contrary in this letter or otherwise, if you are a “specified employee” within the meaning of Section
409A at the time of your termination (other than due to death), then the Deferred Payments, if any, that are payable within the
first six (6) months following your separation from service, will become payable on the first payroll date that occurs on or after
the date six (6) months and one (1) day following the date of your separation from service. All subsequent Deferred Payments,
if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything
herein to the contrary, if you die following your separation from service, but prior to the six (6) month anniversary of your
separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as
administratively practicable after the date of your death and all other Deferred Payments will be payable in accordance with the
payment schedule applicable to each payment or benefit. Each payment, installment and benefit payable under this letter is intended
to constitute a separate payment for purposes of U.S. Treasury Regulation Section 1.409A-2(b)(2).

 

    	 

    	 

    

 

Any
amount paid under this letter that qualifies as a payment made as a result of an involuntary separation from service pursuant
to U.S. Treasury Regulation Section 1.409A-1(b)(9)(iii) that does not exceed the Section 409A Limit will not constitute a Deferred
Payment.

 

For
purposes of this letter, “Section 409A Limit” will mean one (1) times the lesser of: (i) your annualized compensation
based upon the annual rate of pay paid to you during your taxable year preceding the taxable year of your separation from service
as determined under U.S. Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued
with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17)
of the Code for the year in which your separation from service occurs.

 

All
reimbursements and in-kind benefits under this letter that provide for a “deferral of compensation” within the meaning
of Section 409A (i) shall be made no later than the last day of the calendar year that immediately follows the calendar year in
which Employee incurred the expense; (ii) not be subject to liquidation or exchange for another benefit or payment; (iii) provided
to Employee in any calendar year shall not affect the expenses eligible for reimbursement or in-kind benefits to be provided in
any other calendar year; and (iv) except as specifically provided herein, any such reimbursements or in-kind benefits must be
for expenses incurred and benefits provided on or prior to termination (except that a plan providing medical or health benefits
may, to the extent permitted by Section 409A impose a generally applicable limit that may be reimbursed or paid). To the extent
applicable, reimbursements that provide for a “deferral of compensation” within the meaning of Section 409A are intended
to constitute compliant deferred compensation payable on a specified date or fixed schedule in accordance with the requirements
set forth under U.S. Treasury Regulation Section 1.409A-3(i)(1)(iv).

 

The
foregoing provisions are intended to be exempt from or comply with the requirements of Section 409A so that none of the severance
payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities
or ambiguous terms herein will be interpreted to be exempt or so comply. You and the Company agree to work together in good faith
to consider amendments to this letter agreement and to take such reasonable actions which are necessary, appropriate or desirable
to avoid imposition of any additional tax or income recognition prior to actual payment to you under Section 409A.Exhibit
10.3

 

MUTUAL
TERMINATION OF AMENDED AND RESTATED COOPERATIVE 

 

MARKETING
AGREEMENT

 

The
Amended and Restated Cooperative Marketing Agreement (this “Agreement”) was entered into and effective
March 1, 2017 (the “Effective Date") between PRN Physician Recommended Nutriceuticals, LLC, a Delaware
limited liability company with a principal place of business located at 5 Sentry Parkway, East Bldg. Suite 210, Blue Bell, PA
19422 (“PRN”) and TearLab Research, Inc., a Delaware Corporation with a principal place of business
located at 9980 Huennekens St., Suite 100, San Diego, California, 92121 (“Tear”). Each of Tear and PRN is referred
to individually as a “Party” and collectively as the “Parties.”

 

BACKGROUND

 

A.       Both
Parties have agreed to mutually terminate the Agreement.

 

B.       Both
Parties wish to work together to effectively transition customers and revenue generated under the Agreement into future PRN promotion
and marketing efforts.

 

C.       Both
Parties wish to clarify rights and obligations as a result of the termination.

 

NOW,
THEREFORE, in consideration of the mutual covenants, representations, warranties and agreements contained herein, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be bound
hereby, the Parties hereby agree as follows:

 

AGREEMENT

 

1.1       
The Agreement will terminate effective June 23, 2017. Both parties will agree to any joint written communications to current customers
as well as jointly agree on “Talking Points” to be used by both Parties in any verbal communication with customers.

 

1.2       Neither
Party will disparage the other in discussing the Agreement and the reasons for mutual termination of the Agreement

 

1.3       Tear
will be required to file a form 8K with the United States Securities and Exchange Commission regarding changes to a material agreement.
Tear will share a draft of the form 8K with PRN for comment prior to filing and reasonably attempt to incorporate any comments
from PRN, but Tear has the sole right to determine the regulatory content of the final form 8K.

 

    	Page |1 	 	 

    	 

    

 

1.4       All
Escrow amounts generated from the Agreement will be transferred to PRN.

 

1.5       All
payments under section 6 of the Agreement, excluding Escrow amounts, will be paid by PRN to Tear on or before June 30, 2017.

 

1.6       With
regards to non-competition, PRN will separately notify Tear per section 16.2 of the Agreement PRN’s decision in regards
to non-competition post termination of the Agreement.

 

1.7       This
mutual termination does not change section 17.6 which outlines sections surviving termination of the Agreement. 

 

(Rest
of this page left intentionally blank)

 

    	Page |2 	 	 

    	 

    

 

IN
WITNESS WHEREOF, each of the Parties has by its duly authorized representative signed this Agreement as of the day and year
written below.

 

	TEARLAB
    RESEARCH, INC. 	 	PRN
    PHYSICIAN RECOMMENDED NUTRICEUTICALS, LLC
	 	 	 
	By:	/s/
    Wes Brazell	 	By:	/s/
    Stefan Schoen
	Name:	Wes
    Brazell	 	Name:	Stefan
    Schoen
	Title:	CFO	 	Title:	SVP,
    BD
	 	 	 	 	 
	Date:	June
    22, 2017	 	Date:	June
    22, 2017

 

    	Page |3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]